Metabolically re-modeling the drug pipeline

Current Opinion in Pharmacology

Volumn 13, Issue 5, 2013, Pages 778-785

  Oberhardt, Matthew A ^a   Yizhak, Keren ^a   Ruppin, Eytan ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CHORISMIC ACID; HALOFANTRINE; TORCETRAPIB;

ARTICLE; COMPUTER PREDICTION; DRUG DESIGN; DRUG DEVELOPMENT; DRUG SCREENING; DRUG SELECTIVITY; DRUG TARGETING; DRUG TOXICITY; ESCHERICHIA COLI; GENOME SCALE METABOLIC MODEL; HUMAN; HYPERTENSION; KIDNEY CANCER; LEISHMANIA MAJOR; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; SYSTEMS BIOLOGY; VIBRIO VULNIFICUS;

DRUG DISCOVERY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GENOMICS; HUMANS; METABOLOMICS; MODELS, BIOLOGICAL;

EID: 84892974755     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2013.05.006     Document Type: Review

References (69)

1. Kessel M: The problems with today's pharmaceutical business - an outsider's view. Nat Biotechnol 2011, 29: 27-33.
2. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL: How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov 2010, 9: 203-214.
3. Munos B: Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov 2009, 8: 959-968.
4. Cuatrecasas P: Drug discovery in jeopardy. J Clin Invest 2006, 116: 2837-2842. (Pubitemid 44684465)
5. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J: Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009, 48: 1-12.
6. Hopkins AL: Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 2008, 4: 682-690.
7. Reed JL: Shrinking the metabolic solution space using experimental datasets. PLoS Comput Biol 2012, 8:e1002662.
8. Henry CS, DeJongh M, Best AA, Frybarger PM, Linsay B, Stevens RL: High-throughput generation, optimization and analysis of genome-scale metabolic models. Nat Biotechnol 2010, 28: 977-982.
9. Duarte NC, Becker SA, Jamshidi N, Thiele I, Mo ML, Vo TD, Srivas R, Palsson BO: Global reconstruction of the human metabolic network based on genomic and bibliomic data. Proc Natl Acad Sci U S A 2007, 104: 1777-1782. (Pubitemid 46239855)
10. Ma H, Sorokin A, Mazein A, Selkov A, Selkov E, Demin O, Goryanin I: The Edinburgh human metabolic network reconstruction and its functional analysis. Mol Syst Biol 2007, 3.
11. Thiele I, Swainston N, Fleming RMT, Hoppe A, Sahoo S, Aurich MK, Haraldsdottir H, Mo ML, Rolfsson O, Stobbe MD et al.: A community-driven global reconstruction of human metabolism. Nat Biotechnol 2013, 31:419-425 (advance online publication).
12. Sahoo S, Thiele I: Predicting the impact of diet and enzymopathies on human small intestinal epithelial cells. Hum Mol Genet 2013.
13. Bordbar A, Mo ML, Nakayasu ES, Schrimpe-Rutledge AC, Kim Y-M, Metz TO, Jones MB, Frank BC, Smith RD, Peterson SN et al.: Model-driven multi-omic data analysis elucidates metabolic immunomodulators of macrophage activation. Mol Syst Biol 2012, 8.
14. Jerby L, Shlomi T, Ruppin E: Computational reconstruction of tissue-specific metabolic models: application to human liver metabolism. Mol Syst Biol 2010, 6.
15. Folger O, Jerby L, Frezza C, Gottlieb E, Ruppin E, Shlomi T: Predicting selective drug targets in cancer through metabolic networks. Mol Syst Biol 2011, 7:501.
16. Agren R, Bordel S, Mardinoglu A, Pornputtapong N, Nookaew I, Nielsen J: Reconstruction of genome-scale active metabolic networks for 69 human cell types and 16 cancer types using INIT. PLoS Comput Biol 2012, 8:e1002518.
17. Wang Y, Eddy J, Price N: Reconstruction of genome-scale metabolic models for 126 human tissues using mCADRE. BMC Syst Biol 2012, 6:153.
18. Shlomi T, Cabili MN, Herrgård MJ, Palsson BØ, Ruppin E: Network-based prediction of human tissue-specific metabolism. Nat Biotechnol 2008, 26: 1003-1010.
19. Gille C, Bolling C, Hoppe A, Bulik S, Hoffmann S, Hubner K, Karlstadt A, Ganeshan R, Konig M, Rother K et al.: HepatoNet1: a comprehensive metabolic reconstruction of the human hepatocyte for the analysis of liver physiology. Mol Syst Biol 2010, 6.
20. Chang RL, Xie L, Xie L, Bourne PE, Palsson B: Drug off-target effects predicted using structural analysis in the context of a metabolic network model. PLoS Comput Biol 2010, 6:e1000938.
21. Lewis NE, Schramm G, Bordbar A, Schellenberger J, Andersen MP, Cheng JK, Patel N, Yee A, Lewis RA, Eils R et al.: Large-scale in silico modeling of metabolic interactions between cell types in the human brain. Nat Biotechnol 2010, 28: 1279-1285.
22. Mardinoglu A, Agren R, Kampf C, Asplund A, Nookaew I, Jacobson P, Walley AJ, Froguel P, Carlsson LM, Uhlen M et al.: Integration of clinical data with a genome-scale metabolic model of the human adipocyte. Mol Syst Biol 2013, 9.
23. Rantanen A, Rousu J, Jouhten P, Zamboni N, Maaheimo H, Ukkonen E: An analytic and systematic framework for estimating metabolic flux ratios from 13C tracer experiments. BMC Bioinformatics 2008, 9:266.
24. Schuetz R, Zamboni N, Zampieri M, Heinemann M, Sauer U: Multidimensional optimality of microbial metabolism. Science 2012, 336: 601-604.
25. Fong SS, Joyce AR, Palsson BO: Parallel adaptive evolution cultures of Escherichia coli lead to convergent growth phenotypes with different gene expression states. Genome Res 2005, 15: 1365-1372. (Pubitemid 41400902)
26. Burgard A, Maranas C: Optimization-based framework for inferring and testing hypothesized metabolic objective functions. Biotechnol Bioeng 2003, 82: 670-677. (Pubitemid 36576230)
27. Byrne D, Dumitriu A, Segre D: Comparative multi-goal tradeoffs in systems engineering of microbial metabolism. BMC Syst Biol 2012, 6:127.
28. Bordbar A, Palsson BO: Using the reconstructed genome-scale human metabolic network to study physiology and pathology. J Intern Med 2012, 271: 131-141.
29. Chavali AK, D'Auria KM, Hewlett EL, Pearson RD, Papin JA: A metabolic network approach for the identification and prioritization of antimicrobial drug targets. Trends Microbiol 2012, 20: 113-123.
30. Swinney DC, Anthony J: How were new medicines discovered? Nat Rev Drug Discov 2011, 10: 507-519.
31. Rask-Andersen M, Almen MS, Schioth HB: Trends in the exploitation of novel drug targets. Nat Rev Drug Discov 2011, 10: 579-590.
32. Bunnage ME: Getting pharmaceutical R&D back on target. Nat Chem Biol 2011, 7: 335-339.
33. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V et al.: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res 2011, 39:D1035-D1041.
34. Schuster S, Dandekar T, Fell DA: Detection of elementary flux modes in biochemical networks: a promising tool for pathway analysis and metabolic engineering. Trends Biotechnol 1999, 17: 53-60. (Pubitemid 29332898)
35. Oh YK, Palsson BO, Park SM, Schilling CH, Mahadevan R: Genome-scale reconstruction of metabolic network in bacillus subtilis based on high-throughput phenotyping and gene essentiality data. J Biol Chem 2007, 282: 28791-28797.
36. Hopkins AL, Groom CR: The druggable genome. Nat Rev Drug Discov 2002, 1: 727-730. (Pubitemid 37361545)
37. Chavali AK, Blazier AS, Tlaxca JL, Jensen PA, Pearson RD, Papin JA: Metabolic network analysis predicts efficacy of FDA-approved drugs targeting the causative agent of a neglected tropical disease. BMC Syst Biol 2012, 6:27.
38. Shen Y, Liu J, Estiu G, Isin B, Ahn YY, Lee DS, Barabasi AL, Kapatral V, Wiest O, Oltvai ZN: Blueprint for antimicrobial hit discovery targeting metabolic networks. Proc Natl Acad Sci U S A 2010, 107: 1082-1087.
39. Henriksen ST, Liu J, Estiu G, Oltvai ZN, Wiest O: Identification of novel bacterial histidine biosynthesis inhibitors using docking, ensemble rescoring, and whole-cell assays. Bioorg Med Chem 2010, 18: 5148-5156.
40. Yeh I, Hanekamp T, Tsoka S, Karp PD, Altman RB: Computational analysis of Plasmodium falciparum metabolism: organizing genomic information to facilitate drug discovery. Genome Res 2004, 14: 917-924. (Pubitemid 38660510)
41. Rahman SA, Schomburg D: Observing local and global properties of metabolic pathways: 'load points' and 'choke points' in the metabolic networks. Bioinformatics 2006, 22: 1767-1774. (Pubitemid 44288340)
42. Kim HU, Kim TY, Lee SY: Genome-scale metabolic network analysis and drug targeting of multi-drug resistant pathogen Acinetobacter baumannii AYE. Mol Biosyst 2010, 6: 339-348.
43. Kim PJ, Lee DY, Kim TY, Lee KH, Jeong H, Lee SY, Park S: Metabolite essentiality elucidates robustness of Escherichia coli metabolism. Proc Natl Acad Sci U S A 2007, 104: 13638-13642. (Pubitemid 350003373)
44. Kim TY, Kim HU, Lee SY: Metabolite-centric approaches for the discovery of antibacterials using genome-scale metabolic networks. Metab Eng 2010, 12: 105-111.
45. Kim HU, Kim SY, Jeong H, Kim TY, Kim JJ, Choy HE, Yi KY, Rhee JH, Lee SY: Integrative genome-scale metabolic analysis of Vibrio vulnificus for drug targeting and discovery. Mol Syst Biol 2011, 7:460.
46. Frezza C, Zheng L, Folger O, Rajagopalan KN, MacKenzie ED, Jerby L, Micaroni M, Chaneton B, Adam J, Hedley A et al.: Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase. Nature 2011, 477: 225-228.
47. Parsippany (Ed): The Use of Medicines in the United States: Review of 2011. NJ: IMS Institute for Healthcare Informatics; 2012.
48. Oberhardt MA, Palsson BO, Papin JA: Applications of genome-scale metabolic reconstructions. Mol Syst Biol 2009, 5:320.
49. Brynildsen MP, Winkler JA, Spina CS, MacDonald IC, Collins JJ: Potentiating antibacterial activity by predictably enhancing endogenous microbial ROS production. Nat Biotechnol 2013, 31: 160-165.
50. Neal EG, Chaffe H, Schwartz RH, Lawson MS, Edwards N, Fitzsimmons G, Whitney A, Cross JH: The ketogenic diet for the treatment of childhood epilepsy: a randomised controlled trial. Lancet Neurol 2008, 7: 500-506.
51. Bordbar A, Lewis NE, Schellenberger J, Palsson BO, Jamshidi N: Insight into human alveolar macrophage and M. tuberculosis interactions via metabolic reconstructions. Mol Syst Biol 2010, 6.
52. Facchetti G, Zampieri M, Altafini C: Predicting and characterizing selective multiple drug treatments for metabolic diseases and cancer. BMC Syst Biol 2012, 6:115.
53. Oberhardt MA, Goldberg JB, Hogardt M, Papin JA: Metabolic network analysis of Pseudomonas aeruginosa during chronic cystic fibrosis lung infection. J Bacteriol 2010, 192: 5534-5548.
54. Roberts SB, Robichaux JL, Chavali AK, Manque PA, Lee V, Lara AM, Papin JA, Buck GA: Proteomic and network analysis characterize stage-specific metabolism in Trypanosoma cruzi. BMC Syst Biol 2009, 3:52.
55. Huthmacher C, Hoppe A, Bulik S, Holzhutter HG: Antimalarial drug targets in Plasmodium falciparum predicted by stage-specific metabolic network analysis. BMC Syst Biol 2010, 4:120.
56. Lobel L, Sigal N, Borovok I, Ruppin E, Herskovits AA: Integrative genomic analysis identifies isoleucine and CodY as regulators of Listeria monocytogenes virulence. PLoS Genet 2012, 8:e1002887.
57. Rosenbloom KR, Dreszer TR, Long JC, Malladi VS, Sloan CA, Raney BJ, Cline MS, Karolchik D, Barber GP, Clawson H et al.: ENCODE whole-genome data in the UCSC Genome Browser: update 2012. Nucleic Acids Res 2012, 40:D912-D917.
58. Jamshidi N, Palsson BO: Systems biology of SNPs. Mol Syst Biol 2006, 2:38.
59. Chandrasekaran S, Price ND: Probabilistic integrative modeling of genome-scale metabolic and regulatory networks in Escherichia coli and Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 2010, 107: 17845-17850.
60. Karr JR, Sanghvi JC, Macklin DN, Gutschow MV, Jacobs JM, Bolival B Jr, Assad-Garcia N, Glass JI, Covert MW: A whole-cell computational model predicts phenotype from genotype. Cell 2012, 150: 389-401.
61. De Buck SS, Sinha VK, Fenu LA, Nijsen MJ, Mackie CE, Gilissen RA: Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs. Drug Metab Dispos 2007, 35: 1766-1780. (Pubitemid 47481568)
62. van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, Visser CE, Kuijper EJ, Bartelsman JF, Tijssen JG et al.: Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013, 368: 407-415.
63. Freilich S, Zarecki R, Eilam O, Segal ES, Henry CS, Kupiec M, Gophna U, Sharan R, Ruppin E: Competitive and cooperative metabolic interactions in bacterial communities. Nat Commun 2011, 2:589.
64. Zhuang K, Ma E, Lovley DR, Mahadevan R: The design of long-term effective uranium bioremediation strategy using a community metabolic model. Biotechnol Bioeng 2012, 109: 2475-2483.
65. Kim TY, Sohn SB, Kim HU, Lee SY: Strategies for systems-level metabolic engineering. Biotechnol J 2008, 3: 612-623. (Pubitemid 351803371)
66. Li L, Zhou X, Ching WK, Wang P: Predicting enzyme targets for cancer drugs by profiling human metabolic reactions in NCI- 60 cell lines. BMC Bioinformatics 2010, 11:501.
67. Nam H, Lewis NE, Lerman JA, Lee DH, Chang RL, Kim D, Palsson BO: Network context and selection in the evolution to enzyme specificity. Science 2012, 337: 1101-1104.
68. Pal C, Papp B, Lercher MJ, Csermely P, Oliver SG, Hurst LD: Chance and necessity in the evolution of minimal metabolic networks. Nature 2006, 440: 667-670.
69. Yizhak K, Tuller T, Papp B, Ruppin E: Metabolic modeling of endosymbiont genome reduction on a temporal scale. Mol Syst Biol 2011, 7.